Literature DB >> 29027645

Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.

Hitoshi Kawazoe1, Satomi Sumikawa2, Kana Nakauchi3, Yoshihiro Yakushijin4, Yuji Yamamoto5, Yuji Watanabe5, Akihiro Tanaka2, Hiroaki Araki2.   

Abstract

Background Venous pain induced by peripheral intravenous administration of oxaliplatin remains clinically unresolved. Objective The aim of this study was to determine the efficacy of comprehensive intervention care for venous pain in colorectal cancer patients receiving oxaliplatin. Setting A Japanese tertiary hospital. Method We treated all outpatients after April 2012 with comprehensive intervention care including pre-warming of the oxaliplatin solution, use of a hot compress, and pH adjustment by combination with dexamethasone. We retrospectively reviewed the electronic medical records from colorectal cancer patients who had received oxaliplatin via a peripheral vein between December 2009 and June 2014. Main outcome measures The primary endpoint of this study was the incidence of venous pain at the administration site during oxaliplatin infusion, according to injection site reaction grade ≥ 2. Results We evaluated 271 treatment courses in 59 patients. Venous pain occurred in 42 courses (15.5%) among 26 patients. Multivariate logistic regression analysis revealed that female gender and body mass index ≥ 25 kg/m2 were significantly associated with an increased risk of venous pain during all courses (adjusted odds ratio [OR]: 3.18, 95% confidence interval [CI] 1.35-7.92; P < 0.01; and adjusted OR: 3.37, 95% CI 1.26-9.40; P = 0.02, respectively), whereas comprehensive intervention care were significantly associated with reduced risk of venous pain during all courses (adjusted OR: 0.10, 95% CI 0.02-0.44; P < 0.01). Conclusion Comprehensive intervention care is a clinical treatment option for oxaliplatin-induced peripheral venous pain in patients with colorectal cancer, especially females with obesity.

Entities:  

Keywords:  Dexamethasone; Hot compress; Oxaliplatin; Pre-warming; Venous pain

Mesh:

Substances:

Year:  2017        PMID: 29027645     DOI: 10.1007/s11096-017-0536-1

Source DB:  PubMed          Journal:  Int J Clin Pharm


  13 in total

1.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Authors:  Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

2.  [Etiology and management of venous pain during intravenous administration of oxaliplatin].

Authors:  Kazuyo Matsuyama; Hideyuki Mishima; Hiroyuki Ueno; Kinuyo Kajihara; Akiko Morioka; Shigefumi Morimoto; Kazutaka Yamauchi; Yoshihisa Honda; Katsuya Komori; Toshimasa Tsujinaka
Journal:  Gan To Kagaku Ryoho       Date:  2011-03

3.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

4.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

5.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

6.  High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.

Authors:  Kiyotaka Yoh; Seiji Niho; Koichi Goto; Hironobu Ohmatsu; Kaoru Kubota; Ryutaro Kakinuma; Yutaka Nishiwaki
Journal:  Jpn J Clin Oncol       Date:  2004-04       Impact factor: 3.019

7.  Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO).

Authors:  Taishi Hata; Michitaka Honda; Michiya Kobayashi; Akihiro Toyokawa; Masahiro Tsuda; Yukihiko Tokunaga; Kozo Takase; Masakazu Miyake; Satoshi Morita; Naoki Nagata; Junichi Sakamoto; Masahiko Gosho; Hideyuki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-11       Impact factor: 3.333

8.  [Risk Factors for Oxaliplatin-Induced Phlebitis and Venous Pain, and Evaluation of the Preventive Effect of Preheating with a Hot Compress for Administration of Oxaliplatin].

Authors:  Kana Nakauchi; Hitoshi Kawazoe; Risa Miyajima; Chieko Waizumi; Yuki Rokkaku; Kikue Tsuneoka; Noriko Higuchi; Mitsuko Fujiwara; Yoh Kojima; Yoshihiro Yakushijin
Journal:  Gan To Kagaku Ryoho       Date:  2015-11

9.  [Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain].

Authors:  Risa Miyajima; Hitoshi Kawazoe; Kikue Tsuneoka; Mitsuko Fujiwara; Yoh Kojima; Yoshihiro Yakushijin
Journal:  Gan To Kagaku Ryoho       Date:  2013-04

10.  Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Authors:  Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Masato Nakamura; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
Journal:  Lancet Oncol       Date:  2013-11-11       Impact factor: 41.316

View more
  2 in total

1.  Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin.

Authors:  Taisuke Matsuoka; Yoichiro Yoshida; Naoya Aisu; Teppei Yamada; Ai Mogi; Akira Komono; Ryohei Sakamoto; Daibo Kojima; Gumpei Yoshimatsu; Fumiaki Kiyomi; Shohta Kodama; Suguru Hasegawa
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

2.  Gold nanorods together with HSP inhibitor-VER-155008 micelles for colon cancer mild-temperature photothermal therapy.

Authors:  Xichuan Tang; Liwei Tan; Kun Shi; Jinrong Peng; Yao Xiao; Wenting Li; Lijuan Chen; Qian Yang; Zhiyong Qian
Journal:  Acta Pharm Sin B       Date:  2018-06-05       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.